References in periodicals archive ?
T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without GVHD in Children and Adults With Relapsed, Refractory ALL[ 67 ]
This study report, which provides select results from a group of cell therapy trials conducted by investigators at the Children's Hospital of Philadelphia and the University of Pennsylvania, used the chimeric antigen receptor (CAR) cell engineering approach to manipulate the T cells of 22 children and five adults with relapsed, treatment-resistant acute lymphocytic leukemia.
2]T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia.
Chimeric antigen receptor T cell based immunotherapy constitutes a novel, individualized method of combating cancers.
Forward-looking statements include statements about Sorrento's prospects, including, but not limited to any statements about the NanoVelcro Circulating Tumor Cell (CTC) assay technology; chimeric antigen receptor (CAR) T cell programs; potential combination therapies, Sorrento's expectations for adoptive cellular immunotherapies, Sorrento's collaborations with NantKwest, NantCell, NantPharma and NantBioScience, and the development of adoptive immunotherapies and the biosimilar/biobetter programs; Sorrento's ability to leverage the expertise of its employees and partners to assist the company in the execution of its strategies; Sorrento's advances made in developing RTX, CAR.
CAR T cell Genetically engineered T cells with surface receptors (called chimeric antigen receptors or CARs) that bind to a specific antigen on tumor cells.
This high false-negative rate likely occurs because of the inability of consensus V primers to recognize complementary DNA sequences in all of the V segments and because of the inability of V and J primers to recognize genetic alterations such as partial rearrangements (DJ rearrangements) and chromosomal translocations and somatic mutations involving the antigen receptor gene loci [14,18].
In addition, subject to the terms of the agreement, Lilly will make a $30 million equity investment in BioNTech's subsidiary, Cell & Gene Therapies GmbH, which specializes in the research and development of TCR and chimeric antigen receptor immunotherapeutics.
Under the terms of the agreement, the companies worked together to define important characteristics of T cell antigen receptors (TCRs) to develop a foundation for drug discovery targeted at autoimmune disorders.
Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells (Abstract #551; December 8, 3:45 PM)[sup.
In both models, administration of the peptides resulted in reduced titres of anti-AChR antibodies and lower numbers of anti-AChR T-cells, based on the induction of antibodies that bound to the corresponding B and T cell antigen receptors.
26, 2014 /PRNewswire/ -- CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund.